CORE--PHOTOSENSITIZER EVALUATION

本项目的重点之一是开发新的酞菁。 (PC)具有更好抗肿瘤性能的光敏剂(PS)用于光动力疗法。这个 《光敏剂评价核心》的目的是建立基础 项目1中合成的Pc-PS的体外和体内数据 为此，核心将提供标准化生成的信息 分析。每个新合成的PS将同时进行评估 PC 4，化合物的光动力效能将被评为 标准化考试系统作为Pc4的“劣”、“等”或“优”。 结果将被传达给项目调查人员。这个 与Pc4相关的新合成化合物的排名选择是 因为a)这是前10个化合物中的先导化合物 B)其他项目有相当多的经验和 关于这种化合物的初步数据。这一核心还将产生更多 关于选定的有希望的个人资料的详细信息。为此，决定 将由项目1-3的调查人员进行。本局局长 核心项目也是项目3的联合调查员，因此将 还参与决策、实验设计和数据 对这些研究的解释。核心将执行以下操作 六大功能： 1.我们将确定新合成的PS在 正辛醇VS生理盐水。 2.对PS进行初步的体外评价。 3.我们将定义PS的初始光动力学响应。 4.测定PS在血浆、肿瘤和其他组织中的分布 体内的组织。 5.我们将测定全身毒性和皮肤光敏性 PS的响应，以及 6.我们将研究选定的PS的详细的PDT效应。 测试每个PS的优先顺序将因结构类型而异。 这个‘决策网络’在节目叙述中得到了描述。

One emphasis of this program project is to develop new phthalocyanine (Pc) photosensitizers (PS) with better antitumor properties for PDT. The purpose of the 'photosensitizer evaluation core' is to establish basic in vitro and in vivo data on the Pc PS synthesized in Project 1. For this purpose, the core will provide information generated in standardized analysis. Each newly synthesized PS will be assessed in parallel with Pc 4, and the photodynamic efficacy of the compound will be rated in the standardized test system as 'inferior', 'equal' or 'superior' to Pc 4. The results will be communicated to the program investigators. The choice for ranking of newly synthesized compounds in relation to Pc 4 is made because a) this was the lead compound among the first 10 synthesized, and b) other projects have considerable experience and preliminary data with this compound. This core will also generate more detailed information on selected promising PS. For this, the decision will be made by the investigators of Projects 1-3. The Director of this core Project is also a co-investigator of Project 3, and therefore will also participate in decisions, experimental designs, and data interpretation for these studies. The core will perform the following six functions: 1. We will determine the partitioning of newly synthesized PS between n-octanol vs. saline. 2. We will conduct initial in vitro evaluation of PS. 3. We will define initial PDT responses of PS. 4. We will determine distribution of PS in plasma, tumor and other tissues in vivo. 5. We will determine systemic toxicity and cutaneous photosensitivity responses of PS, and 6. We will study detailed PDT effects of selected PS. The priority for testing each PS will vary with the type of structure. This 'decision network' is described in the program narrative.